Management of myelodysplastic syndromes after failure of response to hypomethylating agents. (Q64885639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

29 April 2020

review article

1 reference

title

Management of myelodysplastic syndromes after failure of response to hypomethylating agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

Guillermo Montalban-Bravo

29 April 2020

author

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

29 April 2020

author name string

Angela Gil-Perez

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

29 April 2020

publication date

9 May 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

Therapeutic advances in hematology

29 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

29 April 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

29 April 2020

page(s)

2040620719847059

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34 cells

29 April 2020

cites work

1 reference

12 December 2020

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

12 December 2020

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

12 December 2020

Myelodysplastic syndromes

1 reference

12 December 2020

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

1 reference

12 December 2020

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

12 December 2020

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

1 reference

12 December 2020

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

1 reference

12 December 2020

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

1 reference

12 December 2020

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

1 reference

12 December 2020

A decade of exploring the cancer epigenome — biological and translational implications

1 reference

12 December 2020

Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine

1 reference

12 December 2020

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

12 December 2020

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy

1 reference

12 December 2020

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

1 reference

12 December 2020

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

1 reference

12 December 2020

Toll-like receptor alterations in myelodysplastic syndrome

1 reference

12 December 2020

Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes

1 reference

12 December 2020

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

1 reference

12 December 2020

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

1 reference

12 December 2020

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

1 reference

12 December 2020

Mechanisms of resistance to azacitidine in human leukemia cell lines.

1 reference

12 December 2020

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

1 reference

12 December 2020

Why methylation is not a marker predictive of response to hypomethylating agents.

1 reference

12 December 2020

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

1 reference

12 December 2020

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

1 reference

12 December 2020

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

1 reference

12 December 2020

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

1 reference

12 December 2020

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression

1 reference

12 December 2020

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

1 reference

12 December 2020

Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.

1 reference

12 December 2020

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

1 reference

12 December 2020

Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.

1 reference

12 December 2020

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

1 reference

12 December 2020

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

1 reference

12 December 2020

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

1 reference

12 December 2020

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins

1 reference

12 December 2020

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

1 reference

12 December 2020

Unraveling the molecular pathways of DNA-methylation inhibitors: human endogenous retroviruses induce the innate immune response in tumors

1 reference

12 December 2020

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

1 reference

12 December 2020

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

1 reference

12 December 2020

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

1 reference

12 December 2020

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

1 reference

12 December 2020

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

1 reference

12 December 2020

The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.

1 reference

12 December 2020

Hypomethylating agents after allogeneic blood stem cell transplantation

1 reference

12 December 2020

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes

1 reference

12 December 2020

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

1 reference

12 December 2020

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

1 reference

12 December 2020

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

1 reference

12 December 2020

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

1 reference

12 December 2020

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

1 reference

12 December 2020

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

1 reference

12 December 2020

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.

1 reference

12 December 2020

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

1 reference

12 December 2020

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study

1 reference

12 December 2020

The emerging role of immune checkpoint based approaches in AML and MDS.

1 reference

12 December 2020

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

1 reference

12 December 2020

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

1 reference

12 December 2020

Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

1 reference

12 December 2020

Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.

1 reference

12 December 2020

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

1 reference

12 December 2020

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

1 reference

12 December 2020

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia

1 reference

12 December 2020

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

1 reference

12 December 2020

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

1 reference

12 December 2020

Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes

1 reference

12 December 2020

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

1 reference

12 December 2020

A multi-center Phase 1 trial of ipilimumab in myelodysplastic syndrome patients following hypomethylating agent failure.

1 reference

12 December 2020

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

1 reference

12 December 2020

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

1 reference

12 December 2020

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

1 reference

12 December 2020

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes

1 reference

12 December 2020

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

1 reference

12 December 2020

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

1 reference

12 December 2020

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes

1 reference

12 December 2020

Gilteritinib: First Global Approval

1 reference

12 December 2020

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

1 reference

12 December 2020

Identifiers

DOI

10.1177/2040620719847059

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

29 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31156799 AND SRC:MED&resulttype=core&format=json

29 April 2020

PubMed publication ID

31156799

1 reference